CGAS and neoplasm: Preclinical findings suggest that the use of suboptimal doses of DNA-damaging agents in combination with ICIs or other immunotherapeutics can effectively stimulate tumor-targeting immune responses by increasing the inflammatory response via cGAS activation [394].